Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement

Digestive and Liver Disease

Volumn 37, Issue 6, 2005, Pages 407-417

  Caprilli, R ^a   Angelucci, E ^a   Cocco, A ^a   Viscido, A ^a   Annese, V ^b   Ardizzone, S ^b   Biancone, L ^b   Castiglione, F ^b   Cottone, M ^b   Meucci, G ^b   Paoluzi, P ^b   Papi, C ^b   Sturniolo, G C ^b   Vecchi, M ^b  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b Italian Group for IBD (IG IBD)   (Italy)

Author keywords

Azathioprine; Crohn's disease; Cyclosporine; Immunosuppressive drugs; Inflammatory Bowel diseases; Methotrexate; Mycophenolate mofetil; RAM; RAND method; Tacrolimus; Thalidomide; Ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID; TACROLIMUS; THALIDOMIDE; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; COLON SURGERY; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; ENTERITIS; EVIDENCE BASED MEDICINE; HUMAN; ITALY; MAINTENANCE THERAPY; REMISSION; RISK BENEFIT ANALYSIS; THERAPY RESISTANCE; ULCERATIVE COLITIS; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DRUG COMBINATION; DRUG RESISTANCE; FEMALE; HEALTH CARE QUALITY; HEALTH SERVICE; INTESTINE FISTULA; METHODOLOGY; PREGNANCY; PREGNANCY COMPLICATION; STATISTICS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL AGENTS; HEALTH SERVICES MISUSE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; INTESTINAL FISTULA; ITALY; PREDNISONE; PREGNANCY; PREGNANCY COMPLICATIONS; QUALITY ASSURANCE, HEALTH CARE;

EID: 23644445996     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2004.12.013     Document Type: Article

References (18)

1. Brook R.H., Chassin M.R., Fink A., Solomon D.H., Kosecoff J., Park R.E., et al. A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care 2 (1986) 53-63
2. Brook RH. The RAND/UCLA appropriateness method. In: McCormick KA, Moore SR, Siegel RA, editors. Methodology perspectives, AHCPR Pub. No. 95-0009. Rockville, MD: Public Health Service, U.S. Department of Health and Human Services; 1994. p. 59-70.
3. Best W.R., Becktel J.M., Singleton J.W., and Kern Jr. F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70 (1976) 439-444
4. Sandborn W.J., Feagan B.J., Hanauer S.B., Lochs H., Lofberg R., Modigliani R., et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 122 (2002) 512-530
5. Munkholm P., Langholz, Davidsen M., and Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 35 (1994) 360-362
6. ECCO Consensus Conference on Crohn's Disease. UEGW, Prague, 2004.
7. Truelove Sc., and Witts L.J. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 2 (1955) 1041-1048
8. Caprilli R., Vernia P., Colaneri O., and Torsoli A. A blood pH: a test for assessment of severity in proctocolitis. Gut 17 (1976) 763-769
9. Travis S.P., Farrant J.M., Ricketts C., Nolan D.J., Mortensen N.M., Kettlewell M.G., et al. Predicting outcome in severe ulcerative colitis. Gut 38 (1996) 905-910
10. Pearson D.C., May G.R., Fick G.H., and Sutherland L.R. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 122 (1995) 132-142
11. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev, 2000;2, CD000067.
12. Hanauer S.B., Feagan D.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance Infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 359 (2002) 1541-1549
13. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004) 876-885
14. Feagan B.G., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., Steinhart A.H., et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 342 (2000) 1627-1632
15. Caprilli R., Andreoli A., Capurso L., Corrao G., D'Albaso G., Gioieni A., et al., and the GISC. Oral mesalazine (Asacol) for the prevention of postoperative recurrence of Crohn's disease. Eur J Gastroenterol Hepatol 8 (1994) 35-43
16. Cammà C., Giunta M., Roselli M., and Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 113 (1997) 1465-1473
17. Lichtiger S., Present D.H., Kornbluth A., Gelernt I., Bauer J., Galler G., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330 (1994) 1841-1845
18. Su C.G., Stein R.B., Lewis J.D., and Lichteinstein G.R. Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits?. Dig Liver Dis 32 (2000) 518-531